Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels by Stein, Miguel L., MD, Villanueva, Joyce M., BS, Buckmeier, Bridget K., BA, Yamada, Yoshiyuki, MD, Filipovich, Alexandra H., MD, Assa'ad, Amal H., MD, Rothenberg, Marc E., MD, PhD

Get full text

Long-term outcomes in pediatric-onset esophageal eosinophilia by DeBrosse, Charles W., MD, Franciosi, James P., MD, MS, MSCE, King, Eileen C., PhD, Buckmeier Butz, Bridget K., MHSA, Greenberg, Allison B., BA, Collins, Margaret H., MD, Abonia, J. Pablo, MD, Assa’ad, Amal, MD, Putnam, Philip E., MD, Rothenberg, Marc E., MD, PhD

Get full text

A striking local esophageal cytokine expression profile in eosinophilic esophagitis by Blanchard, Carine, PhD, Stucke, Emily M., BA, Rodriguez-Jimenez, Beatriz, MD, Burwinkel, Karen, BS, Collins, Margaret H., MD, Ahrens, Annette, BA, Alexander, Eileen S., BS, Buckmeier Butz, Bridget K., MS, Jameson, Sean C., BA, Kaul, Ajay, MD, Franciosi, James P., MD, Kushner, Jonathan P., MD, Putnam, Philip E., MD, Abonia, J. Pablo, MD, Rothenberg, Marc E., MD, PhD

Get full text